申请人:LILLY INDUSTRIES LIMITED
公开号:EP0599514A2
公开(公告)日:1994-06-01
Pharmaceutical compounds of the formula
R¹ is phenyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, said phenyl and heteroaryl groups being optionally substituted, or R¹ is furanyl optionally substituted with C₁₋₄ alkyl;
R² is nitrile, carboxy, -COOR⁴ where R⁴ is an ester group, -CONR⁵R⁶ where R⁵ and R⁶ are each hydrogen or C₁₋₄ alkyl, or R⁷SO₂- where R⁷ is C₁₋₄ alkyl or optionally substituted phenyl;
R³ is -NR⁸R⁹, -NHCOR⁸, -N(COR⁸)₂, -N=CHOR⁸ where R⁸ and R⁹ are each hydrogen or C₁₋₄ alkyl, or -NHSO₂R¹⁰ where R¹⁰ is C₁₋₄ alkyl or optionally substituted phenyl; or
where X is C₂₋₄ alkylene; and
the group
represents a pyridine ring fused to the benzopyran nucleus;
and salts thereof.
式中的药物化合物
R¹ 是苯基或选自噻吩基、吡啶基、苯并噻吩基、喹啉基、苯并呋喃基或苯并咪唑基的杂芳基,所述苯基和杂芳基可选择被取代,或者 R¹ 是可选择被 C₁₋₄ 烷基取代的呋喃基;
R² 是腈、羧基、-COOR⁴(其中 R⁴ 是酯基)、-CONR⁵R⁶(其中 R⁵ 和 R⁶ 各为氢或 C₁₋₄ 烷基)或 R⁷SO₂- (其中 R⁷ 是 C₁₋₄ 烷基或任选取代的苯基);
R³ 是-NR⁸R⁹、-NHCOR⁸、-N(COR⁸)₂、-N=CHOR⁸(其中 R⁸ 和 R𠞙 分别是氢或 C₁₋₄ 烷基)或-NHSO₂R¹⁰(其中 R¹⁰ 是 C₁₋₄ 烷基或任选取代的苯基);或
其中 X 是 C₂₋₄ 亚烷基;以及
基团
代表与苯并吡喃核融合的吡啶环;
及其盐类。